A Carrier-Free Nanostructure Based on Platinum(IV) Prodrug Enhances Cellular Uptake and Cytotoxicity
journal contributionposted on 2018-03-09, 00:00 authored by Jingjie Tan, Chan Li, Qian Wang, Shuyi Li, Shizhu Chen, Jinchao Zhang, Paul C. Wang, Lei Ren, Xing-Jie Liang
Flurbiprofen, a hydrophobic COX inhibitor, was coordinated axially with oxoplatin to form a new conjugate, cis,cis,trans-[Pt(IV)(NH3)2Cl2(flurbiprofen)2]. The successful synthesis of this new conjugate was confirmed by 1H, 13C, and 195Pt NMR. The potential of this conjugate being reduced to cisplatin and subsequently exerting its DNA cross-linking ability was verified using cyclic voltammetry (CV), HPLC, and mass spectrometry (MS). This conjugate showed markedly higher cytotoxicity on many cancer cell lines than cisplatin, flurbiprofen, and their physical mixture (mole ratio, cisplatin:flurbiprofen = 1:2). This is consistent with the result of an apoptosis-inducing assay. This conjugate spontaneously assembles carrier-free nanoparticles in aqueous solution, which is confirmed by DLS, TEM, SEM, and AFM, and thus facilitates cellular uptake and markedly improves its cytotoxicity and apoptosis-inducing ability in vitro.
Read the peer-reviewed publication
DNA cross-linking abilitycisplatinCOX inhibitor2 Cl 2mass spectrometryconjugatecancer cell linescyclic voltammetryapoptosis-inducing abilitycarrier-free nanoparticlesCarrier-Free NanostructureSEMHPLCAFM13 CTEM195 Pt NMRflurbiprofenCytotoxicity Flurbiprofen1 HCVcytotoxicityDLSmole ratioMSapoptosis-inducing assay